Welcome to our dedicated page for Organigram Global news (Ticker: OGI), a resource for investors and traders seeking the latest updates and insights on Organigram Global stock.
News about Organigram Global Inc. (NASDAQ: OGI, TSX: OGI) focuses on its activities as a Canadian cannabis cultivator, manufacturer and brand owner operating under the Cannabis Act and Cannabis Regulations. Company announcements highlight its position as Canada’s number one cannabis company by market share in the recreational segment, as well as developments across cultivation, product innovation, beverages and international expansion.
Investors and observers following OGI news will see regular updates on quarterly and annual financial results, including net revenue trends, adjusted gross margin, adjusted EBITDA and free cash flow, as reported in its earnings releases. These updates often discuss the impact of acquisitions such as Motif Labs Ltd. and Collective Project Limited on revenue growth, extraction capabilities and beverage market participation, along with commentary on cost efficiencies and synergy realization.
Organigram’s news flow also covers product and brand launches. Examples include new SHRED gummies formats, Big Bag O’ Buds strains, BOXHOT infused pre-rolls, Trailblazer blunts, Rizzlers vapes and the happly hemp-derived THC brand in the United States. The company highlights its use of FAST™ nanoemulsion technology in ingestible products and describes how these offerings are designed around consumer preferences, including mood-based formulations.
Another important theme in Organigram news is international and policy-related activity. Releases describe record international sales, progress toward EU-GMP certification for the Moncton facility, exclusive genetics agreements with Phylos Bioscience Inc., and polling and economic reports that position legal cannabis as a contributor to Canada’s GDP, jobs and innovation. Corporate governance and leadership updates, such as CEO succession plans and executive appointments, are also communicated through news releases. For a fuller picture of OGI’s evolving strategy and operations, readers can review this ongoing stream of company disclosures.
Organigram is set to supply InterCure with up to 20,000 kg of dried cannabis flower over several years, following a successful 3,000 kg supply agreement fulfilled since June 2020. This new multi-year agreement includes an initial commitment of 10,000 kg with an option for an additional 10,000 kg within three years. Approximately 2,800 kg has already been delivered. The collaboration aims to support both companies’ international expansion strategies, contingent upon compliance with local regulations.
Organigram achieved a record net revenue of $38.1 million in Q3 Fiscal 2022, marking an 88% increase from the previous year. Gross revenue also saw a 90% rise to $55.2 million. The company maintained a 7.8% market share among Canadian licensed producers and remained the top player in dried flower products. New SKUs were introduced, including SHRED-X vapes and CBN Bedtime Blueberry Lemon gummies. However, net loss decreased to $2.8 million, and cash reserves fell by 31% year-over-year.
Organigram Holdings Inc. (NASDAQ: OGI) announced it will report its earnings results for Q3 2022, ending May 31, 2022, on July 14, 2022, before the market opens. A conference call is scheduled for the same day at 8:00 am Eastern Time to discuss the results. Interested participants can register through provided links and access the live call or a replay later. Organigram, a licensed producer of cannabis and cannabis-derived products in Canada, focuses on high-quality products for patients and adult recreational consumers.
Organigram Holdings (OGI) announced its Q2 results ending February 28, 2022, showcasing a remarkable 128% increase in gross revenue to $43.9 million and a net revenue surge of 117% to $31.8 million, marking the highest in company history. The company achieved positive Adjusted EBITDA of $1.6 million two quarters earlier than forecasted. Additionally, it gained a 8.2% market share in Canada, maintaining its top position in the dried flower category. The successful integration of the Laurentian acquisition further boosts its portfolio and market presence.
Organigram Holdings Inc. (NASDAQ: OGI), a top cannabis producer, will report its second quarter 2022 earnings results on April 12, 2022, prior to market opening. The Company will hold a conference call on the same day at 8:00 am ET to discuss the results. Interested parties can register for the call through a provided link and also access a webcast of the discussion. A replay will be available within 24 hours after the call concludes. Organigram focuses on producing quality cannabis products and expanding its international presence.
Organigram Holdings Inc. (NASDAQ: OGI) reports strong market share growth, maintaining the #3 position among Canadian licensed producers and the #1 position in dried flower. The integration of Laurentian Holdings is on track, with expected expansion of its distribution network across nine provinces. New product launches include premium dried flower strains and SHRED’ems line extensions, indicating a commitment to innovation and consumer demand. Overall, these developments support Organigram's market strategy and potential for continued growth.
Organigram Holdings has launched its social impact strategy, ‘Organigram Operating for Good’, aimed at fostering healthy communities. The company has committed to the Pledge 1% Movement, donating 1% of employee time to local volunteer initiatives across Canada. CEO Beena Goldenberg emphasized the importance of community support, stating that as their corporate footprint expands, so should their ability to contribute positively. This initiative aligns with Organigram's ongoing social giving efforts, highlighting a commitment to corporate social responsibility.
Organigram Holdings Inc. (NASDAQ: OGI) announced a C$6.3 million investment from BAT, increasing its equity ownership from 18.8% to 19.5% as of December 31, 2021. This investment follows a previous strategic stake of C$221 million in March 2021, aimed at enhancing product development collaborations. The additional funds will strengthen Organigram's balance sheet, adding to its existing cash position of C$168 million. The company is focused on innovative cannabis products, with the collaboration celebrating its first anniversary on March 10, 2022.
Organigram Holdings announced the results of its annual shareholder meeting held on February 23, 2022. All eight nominees, including Simon Ashton from BAT, were elected to the board. Ashton brings nearly 30 years of finance and leadership experience, enhancing the board's expertise. Additionally, Organigram expanded its Sustainability Committee to include environmental initiatives, reflecting its commitment to sustainability. This strategic move aims to strengthen corporate governance and sustainability efforts.
Thunderbird Entertainment Group has appointed Jérôme Levy to its Board of Directors as an independent member, effective immediately. Levy brings extensive experience in media and entertainment, having previously served as Vice Chairman of Archie Comics. His background includes overseeing TV and film production, digital expansion, and negotiating significant production deals with major companies like Warner Brothers and Netflix. This strategic addition aims to strengthen Thunderbird's leadership and execution of its long-term growth plan, which includes investing in owned-IP and pursuing strategic M&A opportunities.